Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer - Slamon, D J; Eiermann, W; Robert, N J; On Behalf of the BCIRG-006 Investigators (Cancer Res, 2016)
Abstract nr. S5-04